You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

UNIRETIC Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Uniretic patents expire, and when can generic versions of Uniretic launch?

Uniretic is a drug marketed by Ucb Inc and is included in one NDA.

The generic ingredient in UNIRETIC is hydrochlorothiazide; moexipril hydrochloride. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; moexipril hydrochloride profile page.

Paragraph IV (Patent) Challenges for UNIRETIC
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
UNIRETIC Tablets hydrochlorothiazide; moexipril hydrochloride 7.5mg/12.5mg, 15 mg/25 mg and 15 mg/12.5 mg 020729 1 2004-01-15

US Patents and Regulatory Information for UNIRETIC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc UNIRETIC hydrochlorothiazide; moexipril hydrochloride TABLET;ORAL 020729-001 Jun 27, 1997 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Ucb Inc UNIRETIC hydrochlorothiazide; moexipril hydrochloride TABLET;ORAL 020729-003 Feb 14, 2002 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Ucb Inc UNIRETIC hydrochlorothiazide; moexipril hydrochloride TABLET;ORAL 020729-002 Jun 27, 1997 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for UNIRETIC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc UNIRETIC hydrochlorothiazide; moexipril hydrochloride TABLET;ORAL 020729-003 Feb 14, 2002 ⤷  Try a Trial ⤷  Try a Trial
Ucb Inc UNIRETIC hydrochlorothiazide; moexipril hydrochloride TABLET;ORAL 020729-002 Jun 27, 1997 ⤷  Try a Trial ⤷  Try a Trial
Ucb Inc UNIRETIC hydrochlorothiazide; moexipril hydrochloride TABLET;ORAL 020729-002 Jun 27, 1997 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for UNIRETIC

See the table below for patents covering UNIRETIC around the world.

Country Patent Number Title Estimated Expiration
German Democratic Republic 201787 VERFAHREN ZUR HERSTELLUNG VON SUBSTITUIERTEN ACYLDERIVATEN VON 1,2,3,4-TETRAHYDROISOCHINOLIN-3-CARBONSAEUREN ⤷  Try a Trial
Australia 1130588 ⤷  Try a Trial
Israel 63806 SUBSTITUTED ACYL DERIVATIVES OF 1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACIDS,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for UNIRETIC

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0502314 C300095 Netherlands ⤷  Try a Trial PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
0049605 SPC/GB93/099 United Kingdom ⤷  Try a Trial SPC/GB93/099, EXPIRES: 20040413
0443983 C00443983/03 Switzerland ⤷  Try a Trial PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.